Sanofi India - Steady Q1 Ex-Divestments; Focus On Growth Beyond Power Brands: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Sanofi India Ltd.’s Q1 CY22 revenues declined 2.5% YoY, whereas Ebitda margins improved 139 basis points YoY to 27.5% due to lower raw material and employee expenditures.
Subsequently, Ebitda grew 2.7% YoY to Rs 194.5 crore. Adjusted profit after tax increased 4.2% YoY to Rs 152 crore.
Sanofi India completed the transfer of Soframycin and Sofradex brands this quarter and ex-divestment of nutraceutical business last year, revenues are indicative of steady single digit growth.
According to IQVIA MAT March 2022, Sanofi’s top five brands (Lantus, Allegra, Combiflam, Amaryl M and Clexane) has posted YoY growth of 11%.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.